back to US directory
us clinical guidance

Irritable bowel syndrome in adults

ACG-based positive diagnosis, focused exclusion testing, diet, subtype-directed treatment and gut鈥揵rain behavioral care for IBS.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with recurrent abdominal pain related to defecation or altered stool frequency or form and no feature requiring a different urgent pathway. This page addresses positive diagnosis and longitudinal management; inflammatory bowel disease, celiac disease, colorectal cancer, acute infection and pelvic-floor evacuation disorders require their own evaluation.
sources for this section:acg-ibs-2021

The Bottom Line

  • Make a positive symptom-based diagnosis after an appropriate history, examination and limited targeted testing instead of an unlimited diagnosis-of-exclusion work-up.
  • In suspected IBS with diarrhea, test for celiac disease and use fecal calprotectin with C-reactive protein in patients without alarm features to help exclude inflammatory bowel disease.
  • Do not perform routine colonoscopy in patients younger than 45 years with IBS symptoms and no warning sign, while still providing age- and risk-appropriate colorectal-cancer screening.
  • Offer a limited, structured low-FODMAP trial for global symptoms with planned reintroduction and personalization, preferably with a gastrointestinal dietitian to avoid unnecessary long-term restriction.
  • Match pharmacologic treatment to constipation or diarrhea phenotype and predominant pain, and offer gut-directed psychotherapy as an evidence-based treatment rather than implying symptoms are imagined.
sources for this section:acg-ibs-2021

Practical clinical workflow

1
Document pain pattern, Bristol stool form, frequency, urgency, bloating, nocturnal symptoms, bleeding, weight, medicines, infection, diet, family history and the effect on daily life; examine for anemia, mass and pelvic-floor clues.
2
Apply current symptom criteria, order celiac serology and inflammatory markers when indicated, and investigate alarm features or an atypical course rather than labeling them IBS.
3
Explain the disorder of gut鈥揵rain interaction and agree measurable goals; start regular meals, activity and a short diet or fiber intervention suited to subtype and tolerability.
4
Choose an FDA-labeled or guideline-supported subtype treatment after reviewing pregnancy, interactions, gallbladder or pancreatic history and contraindications; reassess global response rather than one isolated symptom.
5
Escalate to gastroenterology, dietetics, pelvic-floor testing or behavioral therapy when diagnosis is uncertain, symptoms remain severe, evacuation dysfunction is suspected or first-line care fails.
sources for this section:acg-ibs-2021

Safety boundaries and escalation

  • Overt bleeding, iron-deficiency anemia, unintentional weight loss, persistent fever, nocturnal progressive symptoms, a palpable mass or strong family history requires targeted evaluation.
  • New severe constipation with vomiting or distention may represent obstruction; acute severe diarrhea with dehydration, blood or systemic toxicity follows an infectious or inflammatory pathway.
  • Do not maintain a highly restrictive diet indefinitely; review nutrition, disordered-eating risk and reintroduction, especially in patients with low weight or multiple exclusions.
  • Product indications differ by IBS subtype and sex, and several agents have important contraindications; check current FDA labeling rather than treating all constipation or diarrhea medicines as equivalent.
sources for this section:acg-ibs-2021

Localization

The ACG guideline is explicitly North American and reflects US tests and FDA-authorized medicines. US colorectal screening starts from the applicable current age and risk framework.
sources for this section:acg-ibs-2021

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of GastroenterologyACG Clinical Guideline: Management of Irritable Bowel SyndromeDOI 10.14309/ajg.0000000000001036 路 published 2021-01-01 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.